Metsera is a new GLP-1 player with a Phase 2b injectable and promising oral and amylin drugs in development. Learn why MTSR ...

Novo Nordisk NVO and Jazz Pharmaceuticals JAZZ reported their first-quarter results. AstraZeneca’s AZN late-stage asthma ...

Numerous studies affirm a truth so many of us have experienced firsthand: Sooner or later, almost every weight-loss plan ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

The National Center for Complementary and Integrative Health states that "research doesn't clearly support using cinnamon for ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Those projections include the impact of tariffs as of May 1, but since that situation might change, there's some uncertainty. Despite the factors that led to its post-earnings decline, Eli Lilly ...

Novo Nordisk shares rose after the Danish obesity-drug maker's first-quarter earnings topped Wall Street expectations. As widely anticipated, the drug maker reduced its growth forecast to reflect the ...

An East Tennessee woman has lost more than 120 pounds in just a year after learning she showed signs of a genetic link to her obesity. UT Medical Center offered her a new medical breakthrough that ...

The iconic weight management brand’s Chapter 11 filing comes as weight-loss drugs such as Ozempic have ascended.

WW International Inc., which has struggled to remain competitive as weight-loss drugs surge in popularity, has filed for ...

In the years leading up to its bankruptcy filing, the company also struggled with the growth of free or low-cost ...